Floatz logo

THIOGUANINE ANHYDROUS

B Acute Lymphoblastic Leukemia

SWOG Cancer Research NetworkSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
73/ 100

Competitive context

140 Active assets in the B Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

THIOGUANINE ANHYDROUS is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
lymphoblastic lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →